***Background.*** S-649266 (\'266) is a novel catechol-substituted siderophore cephalosporin for injection discovered by Shionogi and Co., Ltd. In this study, *in vitro* antibacterial activity of \'266 is evaluated against the clinical isolates of Gram-negative bacteria.

***Methods.*** MIC was measured by broth microdilution method according to Clinical and Laboratory Standard Institute except that CAMHB supplemented with 20 µM of apo-transferrin (apo-T) was used for evaluation of the activity of \'266. In the case of *Acinetobacter baumannii*, Iso-Sensitest Broth (ISB) supplemented with 20 µM of apo-T was used to suppress the trailing effect. Tested isolates were collected from multi-sites in North America, Europe and other regions from 2009 to 2011. Approximately 34% and 23% of tested isolates were resistant to ceftazidime and meropenem respectively.

***Results.*** \'266 showed potent *in vitro* activity against a broad spectrum of Gram-negative bacteria. MIC~90~ of \'266 against 1086 strains of Gram-negative bacteria was 2 µg/mL. MIC~90~ against *Pseudomonas aeruginosa, Stenotrophomonas maltophilia* and most of Enterobacteriaceae were 1 µg/mL or less, and MIC~90~ against *A. baumannii* was 2 µg/mL. These results demonstrated the potent antimicrobial activity of \'266 against a variety of Gram-negative bacteria including strains non-susceptible to ceftazidime, meropenem, levofloxacin or ciprofloxacin.

  Species                            N     MIC~90~ (µg/mL)                       
  -------------------------------- ------ ----------------- ------ ------- ----- ------
  Total isolates                    1086          2          \>32   \>16    \>8   \>32
  *Pseudomonas aeruginosa*          104           1          \>32   \>16    \>8    32
  *Klebsiella pneumoniae*           105         0.12         \>32   0.12    \>8   \>32
  *Escherichia coli*                106           1           2     ≤0.06   \>8    8
  *Stenotrophomonas maltophilia*    108          0.5         \>32   \>16     8    \>32
  *Serratia marcescens*             103         ≤0.06         1       2      2     1
  *Enterobacter aerogenes*          100          0.5         \>32   ≤0.06   0.5    4
  *Enterobacter cloacae*            103           1          \>32   0.12     4     8
  *Citrobacter freundii*            100         0.12         \>32   ≤0.06    8     8
  *Acinetobacter baumannii*         103           2          \>32   \>16    \>8   \>32

***Conclusion.*** S-649266 has potent antimicrobial activity against a variety of Gram-negative bacteria under iron-deficient conditions, suggesting the potential use of \'266 for the treatment of resistant strains.
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